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Glucose tolerance testWe assessed the relationship of insulin resistance with cognitive decline and brain atrophy over two years in
early Alzheimer's disease (AD, n=48) and nondemented controls (n=61). Intravenous glucose tolerance
tests were conducted at baseline to determine insulin area-under-the-curve (AUC). A standard battery of
cognitive tasks and MRI were conducted at baseline and 2-year follow-up. In nondemented controls, higher
baseline insulin AUC was associated with 2-year decline in global cognitive performance (beta=−0.36,
p=0.005). In early AD, however, higher insulin AUC was associated with less decline in global cognitive
performance (beta=0.26, p=0.06), slower global brain atrophy (beta=0.40, p=0.01) and less regional
atrophy in the bilateral hippocampi and cingulate cortices. While insulin resistance is associated with
cognitive decline in nondemented aging, higher peripheral insulin may have AD-speciﬁc beneﬁts or insulin
signaling may be affected by systemic physiologic changes associated with AD. This article is part of a Special
Issue entitled: Imaging Brain Aging and Neurodegenerative disease.: Imaging Brain Aging and
ol of Medicine, Department of
, Kansas 66160, USA. Tel.: +1
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
While insulin is best-known for its peripheral role in stimulating
cellular glucose uptake, its neuromodulatory role in the CNS is
increasingly recognized. Insulin receptors are expressed in all regions
of the brain, with a high density of receptors in the hippocampus,
entorhinal cortex, and olfactory bulb [1,2]. CNS insulin has a minor
role in promoting glucose uptake in glial cells and speciﬁc neural
circuits, including the hippocampal circuit [3]. An extensive amount of
data suggests the cascade of signals triggered by the activated insulin
receptor promotes synaptogenesis and synaptic remodeling [4,5].
Insulin signaling also inﬂuences neuronal survival by protecting
against apoptosis, hypoxic stress, and nitric oxide toxicity [6–8].
While insulin is an important neurotrophic and neuroprotective
factor in the context of an intact insulin signaling system, dysfunction
in the insulin signaling cascade, such as in diabetes mellitus, is
associated with negative health outcomes including dementia and
Alzheimer's disease (AD). Epidemiologic studies of older adults have
found that type 2 diabetes is associated with an increased risk ofsubsequent development of cognitive decline, dementia and AD
[9,10]. The risks are not conﬁned to those with overt diabetes:
individuals with prediabetic states of insulin resistance [11], the
metabolic syndrome [11,12], and hyperinsulinemia [13,14] are also at
an increased risk of developing dementia. Dysfunctional insulin
signaling is also associated with structural brain changes including
whole-brain [15] and medial temporal atrophy [16].
In addition to broad epidemiological associations, insulin signaling
abnormalities are observed in AD and mechanistically related to AD
neuropathology. Individuals with AD have lower levels of insulin in
the cerebrospinal ﬂuid [17] and autopsy studies have demonstrated
fewer insulin receptors and downstream signaling activity in the AD
brain compared to normal controls [18]. Through its actions on GSK3α
and GSK3β, insulin inﬂuences the metabolism of beta-amyloid
peptides [19] and the phosporylation of Tau [20,21]. Clinical data in
humans suggests that insulin may enhance clearance of Aβ from the
CNS [22–24]. Accumulating experimental data suggest that Aβ
triggers downregulation of insulin receptors in neurons, an effect
that is reversed by insulin, suggesting a protective role of insulin in AD
pathogenesis [25]. Exogenously administered insulin has also been
shown to improve cognitive performance in AD [26–29]. The cognitive
beneﬁts of insulin and its apparent inﬂuence on AD-related
neuropathology have driven research into new therapeutic ap-
proaches, such as the use of insulin sensitizers to enhance insulin
signaling [30] and the administration of intranasal insulin to raise
insulin levels in the CNS [31].
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diseases in older adults it is increasingly important to more precisely
deﬁne the role of insulin in brain aging and AD. We previously
examined the relationship of insulin response with cognitive and
imaging data in a cross-sectional study of non-diabetic individuals
with AD. Contrary to our original hypothesis, higher insulin levels
were associated with higher brain volumes, better global cognitive
performance, and lower dementia severity in the AD cohort [32]. Our
data [32] and others [33–36] suggest a relationship reversal in which
insulin-mediated physiology may impact the AD brain differently
than the non-AD brain, or alternatively that AD affects peripheral and
perhaps central insulin-mediated physiology. Understanding the
speciﬁc role of insulin in AD may beneﬁt therapeutic strategies and
biomarker development. Thus, we performed a 2-year longitudinal,
observational study of 109 non-diabetic individuals with and
without AD to assess the relationship of insulin-mediated glucor-
egulation with cognitive and imaging markers reﬂective of AD
progression. We were particularly interested in assessing if a
differential relationship existed across the AD and nondemented
controls given our prior ﬁndings suggesting that insulin was
associated with brain volume and cognition in AD but not
nondemented controls.2. Methods
2.1. Sample and recruitment
Data used in these analyses came from participants enrolled in the
longitudinal Brain Aging Project at the University of Kansas Alzheimer
and Memory Program who had baseline intravenous glucose
tolerance tests and longitudinal cognitive evaluations (baseline and
2-years later). Nondemented older controls (n=61) were without
evidence of functional cognitive decline (Clinical Dementia Rating
[CDR] 0) at both time points. AD participants met criteria for AD [37]
in the very mild (CDR 0.5, n=40) or mild (CDR 1, n=8) stages at
baseline and demonstrated persistent cognitive and functional
impairments 2 years later (CDR≥0.5). Informed consent was
obtained on all participants prior to enrollment into the study.
AD participants were recruited largely by media appeals and from
a referral-based memory clinic. All nondemented participants were
recruited by self-referral in response to media coverage and word of
mouth. Study exclusions at baseline are previously described [32] and
include diabetes mellitus (clinical diagnosis, use of an anti-diabetic
agent, or 2-hour post-load serum glucose N199) and unstable
ischemic heart disease within the last 2 years.2.2. Clinical assessment
The clinical assessment was conducted at baseline and two years
later, as previously described [32]. Dementia severity was determined
using the CDR [38] and change in theCDR sumof box scorewasused as a
measure of progression in dementia severity. A trained psychometrician
administered a standard psychometric battery [32] that included the
Wechsler Memory Scale [WMS]–Revised Logical Memory I and II, Free
and Cued Selective Reminding Task, Boston Naming Test (15 item),
WMS III Digit Span Forwards and Backwards, Wechsler Adult
Intelligence Scale [WAIS] letter–number sequencing, Trailmaking A
and B, Verbal Fluency (animals, fruits, and vegetables), Stroop Color–
Word Test, andWAIS Block Design. Cognitive performance scores were
converted to z-scores based on the mean and standard deviation of 82
nondemented participants and the overall mean served as a composite
measure of global cognitive performance. Cognitive declinewas deﬁned
as change in the global cognition composite from baseline to 2-year
follow-up evaluation.2.3. Intravenous glucose tolerance test
A 14-sample intravenous glucose tolerance test (IVGTT) was
performed at 8:30 AM after a 12-hour overnight fast. An intravenous
glucose bolus of 0.3 g/kg body weight was delivered and blood
samples were drawn over three hours [32]. The total areas-under-the-
curve (AUC) for insulin and glucose were determined by the
trapezoidal rule. Glucose and insulin AUCs served as the primary
measures and secondary measures included fasting and two-hour
post-load insulin and glucose. No participants met criteria for the
diagnosis of diabetes at baseline (two-hour post-load glucose level
≥200 mg/dL). Serum insulin was measured by radioimmunoassay
(Diagnostic Systems Laboratories, Webster,TX) with a sensitivity of
1.3 mU/L.
2.4. Neuroimaging
Structural MRI was obtained using a Siemens 3.0 Tesla Allegra
scanner. T1-weighted anatomic images were acquired to provide
detailed gross anatomy with high gray-white matter contrast (MP-
RAGE; 1×1×1 mm3voxels; TR=2500 ms, TE=4.38 ms, TI=1100 ms,
FOV 256×256 mm2 with 18% oversample, ﬂip angle=8°). Fluid
attenuated inversion recovery (FLAIR) images were used for white
matter lesion assessments (Ti=2500, TR=10,000, TE=81.0, ﬂip
angle=180°, slice thickness=4 mm with 0 gap). Baseline MRI was
missing for 5 nondemented and 3 AD participants (refused, unable, or
inadequate imaging data) and follow-up MRI data was missing on 4
nondemented and 6 AD participants; thus, longitudinal imaging
analyses were performed on 52 nondemented and 39 AD participants.
Participants without complete imaging data were not different from
their overall cohort in key measures of age, education, global cognitive
performance, insulin and glucose measures with one exception: the 9
nondementedparticipantswere slightlymore educated than the overall
nondemented cohort (18.6 years vs 16.3 years, p=0.03).
Baseline brain volumes were determined using the VBM5 toolbox
in MATLAB 7.1 (MathWorks, Natick, MA). Segmentation volumes for
total gray matter (GM), white matter (WM), and cerebrospinal ﬂuid
(CSF) were used to calculate baseline normalizedwhole-brain volume
(% total intracranial volume). Global whole brain atrophy over 2-years
was assessed using Structural Image Evaluation Normalization of
Atrophy (SIENA) [39] which assesses local shifts in brain edges to
estimate percent of brain volume change (PBVC), where negative
numbers represent atrophy.
Longitudinal regional voxel-based analyses were performed
using SPM8 algorithms (Wellcome Department of Cognitive Neurol-
ogy, London) in MATLAB 7.2 on Linux. First, the two-year follow-up
MRIwas rigidly registered onto the subject's baseline image followed
by high dimensional deformation warp resulting in a ﬁeld map of
change (determinant of the Jacobian matrix) at each voxel. The
baseline gray matter segment and Jacobian determinants were
multiplied voxel-by-voxel to form a map of gray matter change.
Next, Diffeomorphic Anatomical Registration Through Exponen-
tiated Lie Algebra (DARTEL) [40] was used to create a customized
template of the atrophymaps through a nonlinear image registration
procedure iteratively matching the images to a template generated
from their ownmean. This DARTEL template and ﬂow ﬁelds from the
template creation were normalized to Montreal Neurological
Institute (MNI) space. The ﬂow ﬁelds and parameters from this
normalization step were applied to gray matter atrophy maps. To
preserve the original tissue volumes, the normalized gray matter
atrophy images weremodulated and smoothedwith an 8 mm isotropic
Gaussian kernal to accommodate inexact spatial normalization.
The normalized, modulated, and smoothed gray matter change
maps for each individual were then analyzed in SPM8. A General
LinearModel (GLM)multiple regression analysis was used to examine
linear relationships of insulin AUC and longitudinal regional gray
Fig. 1. Relationship of insulin and cognitive decline in nondemented controls.Insulin
area under the curve over a three-hour intravenous glucose tolerance test is associated
with cognitive decline over two years in older adults without dementia, with increasing
insulin levels associated with greater decline in cognition. Cognitive measures are
corrected for age, sex, and education and presented in the ﬁgure as standardized values.
Table 1
Sample characteristics.
Nondemented Alzheimer's disease P Value
(n=61) (n=48)
Mean (SD) Mean (SD)
Age, years 73.3 (6.7) 75.2 (6.3) 0.13
Mean follow up, years 2.0 (0.3) 2.0 (0.3) 0.89
Education, years 16.6 (2.8) 15.5 (2.9) 0.04
Female — % (n) 54.1 (33) 56.3 (27) 0.82
ApoE4 carrier, % (n) 29.5 (18) 56.3 (27) 0.01
Body mass index 26.4 (3.9) 26.1 (3.9) 0.75
Hypertension, % (n) 23.0 (14) 43.8 (21) 0.02
Baseline MMSE 29.5 (0.8) 26.1 (3.1) b0.001
MMSE 2-year change −0.3 (1.1) −3.3 (5.3) b0.001
Baseline global cognition
— z score
0.15 (0.49) −1.50 (0.93) b0.001
Global cognition 2-year change −0.04 (0.34) −0.59 (0.64) b0.001
CDR sum of boxes 0.0 (0.1) 2.9 (1.2) b0.001
CDR sum of boxes change 0.0 (0.1) 2.1 (3.2) b0.001
Insulin (3-hour AUC) 2403 (1273) 2910 (1609) 0.07
Fasting insulin (uU/mL) 7.2 (4.6) 8.4 (5.4) 0.19
2-hour insulin (uU/mL) 7.5 (4.4) 10.4 (7.8) 0.03
Glucose (3-hour AUC) 20,808 (5516) 22,911 (3803) 0.03
Fasting glucose (mg/dL) 97.7 (9.0) 100.4 (12.6) 0.19
2-hour glucose (mg/dL) 92.8 (12.4) 96.8 (19.0) 0.19
Baseline brain volume (%TICV) 70.3 (3.3) 67.0 (3.4) b0.001
Brain atrophy
(% brain volume loss)
−0.89 (1.22) −2.80 (2.42) b0.001
White matter lesion burden
(mm3)
11,943 (14,230) 12,871 (15,105) 0.76
All data are means (SD) unless otherwise noted. ApoE4: Apolipoprotein E4 allele. AUC:
area under the curve. TICV: total intracranial volume.
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confounding variables. Voxels are reported with reference to MNI
space. For all analyses, results were considered signiﬁcant at pb0.001
uncorrected for multiple comparisons, with clusters exceeding an
extent threshold of 100 voxels and ZN3.0.
2.5. Covariates
We examined several important covariates that may potentially
mediate a relationship of insulin with brain atrophy or cognitive decline
including Apolipoprotein E4 carrier status, history of hypertension
(reported medical history of hypertension requiring treatment), and
bodymass index (BMI; kg bodyweight/height inmeters2), and physical
activity level using thePhysical Activity Scale in theElderly. Additionally,
whitematter lesionsweremanually tracedonbaselineFLAIR images as a
measureof vascular relatedbrain injuryusingMedical ImageProcessing,
Analysis, and Visualization (Johns Hopkins University) by a single
trained rater and expressed as volume in mm3. Reliability of white
matter assessments were assessed with 10 blinded repeat assessments
inserted randomly into the rater's workﬂow. Intra-rater reliability was
excellent (Intraclass Correlation Coefﬁcient=0.995). Baseline cognitive
performance was used as an additional covariate for analyses assessing
2-year rates of cognitive decline. Baseline brain volume was used as an
additional covariate for analyses assessing 2-year rates of brain atrophy.
2.6. Statistical analyses
Analyses were conducted using SPSS 17.0 (SPSS Inc., Chicago, IL).
Continuous variables were summarized by means and standard
deviations while categorical variables were summarized by frequency
and percent. Student's t-test was used to compare continuous
demographic and imaging variables in early AD and nondemented
groups. A chi square test was used to compare categorical variables.
Linear regression was used to assess the relationship of insulin and
glucose values with two-year rates of cognitive decline and whole
brain atrophy. All analyses were conducted within diagnostic groups
(early AD and nondemented subjects separately) as opposed to the
entire cohort combined. All imaging analyses were adjusted for age
and sex to control for their known inﬂuence on brain size and atrophy
rates. All cognitive analyses were controlled for age, sex, and
education given each variable's known inﬂuence on cognitive
performance. In secondary analyses, we also assessed the role of
additional potential covariates by adding them singly to the
regression model. We did not fully-adjust for all potential covariates
given the large number of covariates and relatively small sample size.
These additional covariates included education, hypertension history,
APOE4 carrier status, physical activity, BMI, white matter lesion
burden, baseline brain volume (atrophy analyses), and baseline
cognitive performance (cognitive performance analyses). Univariate
general linear model was used to examine for the presence of group
(AD vs. nondemented)×insulin/glucose values in predicting cognitive
decline and brain atrophy.
3. Results
3.1. Sample characteristics (Table 1)
The AD and nondemented groups were comparable in age,
education, and sex distribution. The nondemented cohort had minimal
cognitive change over two yearswith amean change of−0.05 standard
deviations (range +0.7 to −1.4) on the global cognitive index
(composite of 12 standard tests). Individuals with AD had lower
baseline cognitive performance and brain volumes and demonstrated
greater rates of cognitive decline and brain atrophy than the
nondemented control group. Modest elevations or trends were
observed for glucose and insulin values in AD compared to nondemen-ted participants. At 2-year follow up, three AD and one nondemented
participant had developed diabetes and were treated with oral agents.
Excluding these participants from the analyses did not alter the
following results (data not shown).3.2. Nondemented aging cohort
3.2.1. Cognitive decline (Table 2)
In nondemented participants, insulin AUC was associated with
decline in global cognition when controlling for age, sex, and education
(beta=−0.35, p=0.006) with greater rates of global cognitive decline
Table 2











Insulin AUC −0.36⁎⁎ −0.04 0.26 (p=0.06) 0.40⁎
Fasting insulin −0.28⁎ −0.05 0.16 0.36⁎
2 h Insulin −0.41⁎⁎ −0.05 0.35⁎ 0.47⁎⁎
Glucose AUC −0.18 0.08 0.31⁎ 0.35⁎
Fasting
glucose
−0.26⁎ −0.03 0.21 0.24
2 h glucose −0.25⁎ −0.03 0.19 0.20
Data represent standardized betas describing the relationship between glucose and
insulin variables (predictor variable) with 2-year rates of cognitive decline and brain
atrophy (dependent variable) in nondemented and early AD cohorts. Cognitive
analyses are controlled for age, sex, and education. Brain atrophy analyses are
controlled for age and sex.
⁎ pb0.05.
⁎⁎ pb0.01.
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additional individual covariates of interest (baseline cognitive perfor-
mance, hypertension history, APOE4 carrier status, physical activity,
BMI, white matter lesion burden) did not change the results. The
secondary insulin response variables of fasting insulin, 2-hour insulin,
fasting glucose, and 2-hour glucose levelswere also inversely associated
with cognitive decline.
In individual cognitive tasks, insulin AUC was associated with
decline in memory performance (Selective Reminding Task; beta=
−0.31, p=0.02), Trailmaking A task (beta=−0.26, p=0.05), and a
trend to greater decline in verbal ﬂuency (beta=−0.22, p=0.08).
3.2.2. Brain atrophy
Insulin AUC was not associated with brain atrophy (beta=−0.04,
p=0.76). In regional atrophy analyses, insulin was not related to
positive or negative change in brain volume.
3.3. Alzheimer's disease cohort
3.3.1. Cognitive decline
In the AD cohort, a trend was observed relating insulin AUC with
cognitive decline (beta=0.26, p=0.06) controlling for age, sex, and
education, with higher insulin AUC associated with less decline over
two years. This relationship of insulin with cognitive decline was
signiﬁcantly different from that observed in nondemented individuals
(group×insulin interaction p=0.007). In analyses of secondary
variables of insulin response, 2-hour insulin (beta=0.35, p=0.01),
and glucose AUC (beta=0.31, p=0.04; group×glucose AUC interac-
tion, pb0.001) were also associated with cognitive decline.
In individual cognitive tasks, insulin AUC was only related to 2-year
change in verbal ﬂuency (beta=0.29, p=0.05).
3.3.2. Brain atrophy
In the AD group, insulin AUC was associated with brain atrophy
when controlling for age and sex (beta=0.39, p=0.01), with higher
insulin AUC associated with less brain atrophy (Fig. 2 and Table 2).
Controlling for additional individual covariates of interest (education,
baseline brain volume, hypertension history, ApoE4 carrier status,
physical activity, BMI, white matter lesion burden) did not attenuate
this relationship. A signiﬁcant group×insulin AUC interaction wasFig. 2. Relationship of insulin and whole brain atrophy in early Alzheimer's
diseaseInsulin area-under-the-curve in response to a three hour intravenous glucose
tolerance test is associated with brain atrophy in individuals with early Alzheimer's
disease, with increasing insulin levels associated with less brain atrophy. Atrophy
measures are corrected for age and sex and presented in the ﬁgure as standardized
values (thus, positive values do not represent increased brain volume over two years).
Brain volume declined in 37 AD participants, was unchanged in one, and increased in
one (0.2%) over the two year study.present in predicting brain atrophy (p=0.02). This demonstrates the
relationship between insulin and brain atrophy was different across
AD and nondemented groups. Secondary measures of fasting insulin,
2-hour insulin, and glucose AUC were similarly related to brain
atrophy (Table 2).
In regional brain atrophy analyses, higher insulin AUC was
associated with less atrophy in limbic regions, including the bilateral
hippocampi and cingulate gyri, left middle temporal gyrus, right
parahippocampal gyrus and right orbitofrontal gyrus. Higher insulin
AUC was associated with greater atrophy of the right inferior frontal
cortex, inferior parietal, superior and temporal cortices and the
putamen (Fig. 3 and Table 3).4. Discussion
Our ﬁndings suggest important differences in the relationship of
peripheral insulin levels with cognitive changes and brain atrophy in
AD and normal aging. In cognitively normal individuals without
diabetes, higher insulin levels in response to a glucose challenge were
associated with increased rates of age-related cognitive decline. In
contrast, there is a distinct reversal of this relationship in individuals
with early AD, where higher insulin and glucose levels were
associated with slower cognitive decline. This ﬁnding was strength-
ened by our longitudinal imaging data which demonstrated higher
insulin and glucose levels in the AD cohort were associatedwith lower
rates of whole brain atrophy and regional atrophy in areas affected by
AD neuropathology such as the hippocampus and cingulate cortices.
These group-speciﬁc relationships suggest insulin signaling may
affect brain health in a disease-speciﬁc manner or that insulin
signaling may be affected by changes in AD brain physiology.
Our ﬁndings in older adults without dementia are consistent with
several studies suggesting that insulin resistance has detrimental
long-term cognitive effects [11,13,14]. Our cognitively normal cohort
was carefully screened for the presence of dementia and mild
cognitive impairment twice over two years by a clinician using a
standard and validated clinical evaluation sensitive to detecting the
earliest clinical changes of AD [38]. Glucose and insulin levels were
inversely associated with age-related cognitive change over two
years, with higher insulin and glucose levels associated with greater
cognitive decline even when controlling for important covariates
including age, sex, hypertension, physical activity level, and BMI.
These ﬁndings are in line with prior studies suggesting that insulin
resistance, even in nondiabetics, is associated with cognitive impair-
ment and risk of cognitive decline [41] and suggest that even mild
variations along a continuum of insulin resistance may be cognitively
Fig. 3. Insulin and regional brain volume in early Alzheimer's diseaseInsulin area-under-the-curve was related to regional atrophy in limbic regions (identiﬁed by yellow,
reﬂecting Z scores N3.25, kN100, pb .001 uncorrected). Results are displayed overlaid on the A) sagittal, B) coronal, and C) axial views of a standard, spatially normalized MRI.
The relationship between insulin and regional atrophy in the cingulate cortex is visible in A and B, the medial temporal cortex in B, and the orbitofrontal cortex in C. The
anatomical location and description of brain regions is in Table 3. D) The scatterplot demonstrates the relationship of insulin and gray matter volume atrophy in the largest
cluster (right hippocampus/parahippocampal gyrus) in individuals with early AD.
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mechanisms through which insulin resistance may inﬂuence cogni-
tion include vascular injury, brain insulin resistance, glucose toxicity,
and advanced glycation end products [42].
The negative association between higher insulin levels and
cognitive change, however, was not observed in our AD cohort. In
contrast, we observed that higher levels of insulin and glucose were
associated with slower cognitive decline over two years in the AD
cohort. This ﬁnding is consistent with our cross-sectional data from a
subset of individuals included in this longitudinal study [32]. This
ﬁnding may also be relevant to two clinical studies suggesting AD
subjects with type II diabetes, which is often accompanied by
hyperinsulinemia, had lower rates of cognitive decline than non-
diabetic AD subjects [33,34]. Notably, our observation was present
despite the absence of anti-diabetic therapies, a mechanism previously
hypothesized to explain the unexpected slower clinical decline
observed in diabetics with AD [33]. Moreover, our longitudinal
neuroimaging data lends additional convergent evidence to these
clinical ﬁndings. We found that higher insulin levels in AD were
associated with less whole brain volume loss over the two-year study.
We also used an optimized voxel-based 3-dimensional longitudinal
analysis method and found less atrophy in relation to higher insulin
levels in regions prominently affected by AD neuropathology, includingTable 3
Areas of gray matter volume change in patients with Alzheimer's Disease and
nondemented elderly correlated with higher and lower insulin AUC over the follow-
up period.
AUCi Region Peak k Z P Value
Coordinate (mm)
Pos Talairach x y z Uncorrected
R Cingulate gyrus 15 −3 38 680 3.92 b.001
L Cingulate gyrus −11 −14 35 809 3.67 b.001
L Middle temporal gyrus/
hippocampus
−46 −20 −16 224 3.48 b.001
R Orbitofrontal gyrus 13 36 −24 683 3.29 0.001
R Hippocampus −24 −14 −13 394 3.28 0.001
R Hippocampus/
Parahippocampal gyrus
−44 −15 −17 1113 3.25 0.001
Neg L Inferior frontal gyrus −50 30 10 372 4.09 b.001
L Superior temporal gyrus −53 12 −4 183 3.62 b.001
L Inferior parietal lobe −41 −47 40 201 3.61 b.001
R Superior temporal pole 65 8 −6 315 3.50 b.001
R Putamen 29 10 −3 141 3.33 b.001the hippocampus and cingulate cortices. Our imaging results suggest
lower AD neuropathological burden could exist in those with higher
insulin levels and converge with autopsy data demonstrating lower
AD-related pathology in diabetics compared to nondiabetics [35,36].
The mechanisms underlying these relationships in our early AD
cohort remain unclear but emerging data suggests an important and
beneﬁcial role for insulin in neurodegenerative disease. Insulin is a
neuroprotective [21] and neurotrophic [43] factor that protects neurons
from amyloid-beta related toxicity [25]. Individuals with ADhave lower
insulin levels in the cerebrospinal ﬂuid [17] and reduced insulin
signaling in the brain [18] compared to those without dementia. Early
results of clinical trials designed to increase CNS levels of insulin suggest
intranasal insulin has memory beneﬁts and alters peripheral amyloid
levels [26]. It is thus possible that increased peripheral insulin levels
commonly observed in AD, and in our AD cohort, may protect against or
compensate for low CNS insulin or aberrant CNS insulin signaling.
It is important to consider the increasingly recognized heterogeneity
in the underlying neuropathological substrate responsible for the AD
dementia syndrome, in particular the role of vascular injury. For
instance, individuals with the AD clinical syndrome and diabetes have
more extensive vascular pathology than those with AD alone [36,44].
Thus, it is feasible that our cohort of AD participants with higher
peripheral insulin levels may also havemore heterogeneous underlying
pathologies (i.e., AD and cerebrovascular disease). This possibility is
relevant to our ﬁndings as AD with diabetes may be associated with
slower clinical decline than those with pure AD [45] while cerebrovas-
cular disease inﬂuences the earlier clinical expression of AD at lower
levels of neuropathological burden [46,47] Nevertheless, we attempted
to account for thepotential confounding inﬂuence of vascular disease by
excluding individuals with a history of stroke or coronary artery disease
and controlling for a measure of vascular burden (white matter lesion
burden) reducing the likelihood of this possibility.
While our data could indicate a role for insulin signaling in the
development and progression of AD, the possibility of “reverse
causation” should be considered. Amyloid deposition has been
reported in the brain and pancreas in AD [48] and reduced insulin
secretion is associated with increased AD risk [49]. Additionally, AD-
related pathological brain changes occur in regions regulating
metabolism and appetite [50] that may result in systemic alterations
in insulin levels. AD pathological changes are associated with
declining body mass index and weight loss years prior to the clinical
onset of AD symptoms [51]. Thus, systemic metabolic changes may be
the result of AD brain changes.
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evidence of signiﬁcant cerebrovascular or coronary artery disease the
results may not be generalizable to a broader population. The lack of
diabetics or individuals with more severe insulin resistance does not
allow us to directly test for the presence of a U-shaped risk curve as
suggested by prior studies linking both low and high insulin levels
with cognitive outcomes [49,52]. Additionally, participants with AD
were in the earliest clinical stages of the disease, with most (83%)
being in the very mild (CDR 0.5) stage. Many of these participants
would meet criteria for MCI, although our methods are accurate in
identifying individuals in the earliest clinical stages of AD [53] and our
cohort progressively declined over two years on clinical, cognitive,
and imaging measures as expected for an early AD cohort. While
insulin and glucose were associated with cognitive decline in
cognitively normal individuals, there was no association with brain
atrophy. This may be related to the reduced variance of brain atrophy
in normal aging compared to that observed in AD thus reducing our
power to resolve a possible association.
In summary, measures of insulin resistance were associated with
cognitive change over two years in our control cohort, as expected,
but not in those with AD. In fact, an elevated insulin response was
associated with better long term cognitive and brain structural
outcomes over two years in individuals with AD. This relationship
reversal suggests insulin-mediated physiology may impact the AD
brain differently than the non-AD brain, or that AD affects peripheral
and perhaps central insulin-mediated physiology. Understanding the
speciﬁc role of insulin and insulin signaling in the AD brain may
beneﬁt AD therapeutic development efforts or contribute to biomark-
er development and help deﬁne an AD-speciﬁc peripheral phenotype.Acknowledgements
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